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PERSPECTIVES IN CLINICAL NEPHROLOGY
The hemolytic uremic syndrome
Hemolytic uremic syndrome (HUS) is a disease of non-immune
hemolytic anemia, thrombocytopenia and renal failure due to
platelet thrombi in the microcirculation of the kidney. It mainly
affects infants and small children, though older children and
adults may also suffer. The characteristic lesion, thrombotic
microangiopathy (TMA) [1], is unique to this syndrome and
consists of vessel wall thickening (capillaries and arterioles), with
swelling and detachment of the endothelial cells from the base-
ment membrane and accumulation of fluffy material in the
subendothelium. Vascular lesions of HUS and of the related
syndrome thrombotic thrombocytopenic purpura (TIP), a sys-
temic form of TMA with neurological signs, are virtually identical
and often indistinguishable from the microvascular lesions of
scleroderma and malignant hypertension [2] (Table 1). Typical
HUS of children manifests with gastrointestinal (sometimes
bloody diarrhea) or respiratory tract prodromes. In atypical and
adult forms the disease may manifest with transient neurological
signs secondary to platelet aggregation and obstruction of brain
microcirculation. Endothelial dysfunction appears to be an impor-
tant factor in the sequence of events leading to the microangio-
pathic process. Consistent with this interpretation are data that
most agents associated with the disease, for example bacterial
endotoxins, verotoxins, antibodies and immunocomplexes, and
certain drugs, are toxic to endothelial cells.
Verotoxin-associated HUS
In the last ten years the cause of gastrointestinal symptoms in
HUS has been widely investigated. In the late 1970s Konowaichuk
and coworkers [3] found that some strains of E. co/i produced
certain exotoxins closely related to the 70 kDa protein encoded in
Shigella dysenteriae DNA. The clinical significance of these
toxins—Shiga-like toxins or verocytotoxins for their effect on
kidney Vero cell lines—remained uncertain until 1983 when Riley
et al [4] reported an association between E. co/i (serotype
0157:H7) infection and two outbreaks of hemorrhagic colitis, and
Karmali et a! [5] found verotoxin-producing E. co/i (VTEC)
infection in 11 of 15 cases of sporadic HUS.
It is now clear that VTEC is associated with a spectrum of
illnesses that include asymptomatic infection, uncomplicated di-
arrhea, hemorrhagic colitis and HUS. Most information on VTEC
is derived from study of the 0157:H7 serotype, easily distinguish-
able from other fecal E. co/i on account of its peculiar biochemical
properties (lack of sorbitol fermentation). More information is
now available on the non-0 157 serotypes and more than 50
different ones may cause the disease in humans.
In 1983 a case-control study from the Centers for Disease
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Control in Atlanta found that ingestion of beef patties eaten at a
fast-food restaurant chain was the cause of hemorrhagic colitis in
47 patients [4]. The same strain of E. co/i was then isolated in 55
of 137 patients presenting for bloody diarrhea [6]. In 1980 Karmali
and coworkers isolated a VTEC strain from the bowel of a patient
who died of HUS. Subsequently the same investigators identified
VTEC infection from six 0 serotypes (026, 0111, 0113, 0121,
0145 and 0157) in 30 out of 40 patients from Ontario and
Quebec with classical HUS [7].
The finding that this otherwise heterogeneous group of E.
co/i all produced verotoxin suggested VTEC causes HUS.
Actually VTEC infection (0157:H7 serotype) has been docu-
mented in 50% of sporadic cases of typical HUS with hemor-
rhagic colitis [8—12]. Lior et al found VTEC infection
(0157:H7 E. co/i in 88% of cases) in all the 176 children with
HUS referred to the Canadian Pediatric Kidney Disease
Research Center [13]. The most devastating outbreak of
0157:H7 E. co/i infection reported so far occurred in a
Canadian nursing home: of 55 residents with hemorrhagic
colitis 12 had HUS and 11 died [12].
At variance with most reports that E. co/i 0157:H7 HUS is a
food-borne disease, Rowe and coworkers in a case-control
study of 565 residents of a remote Inuit community in northern
Canada [14] found that undercooked meat and foods were not
implicated. However, the 19 patients with HUS and the 69 with
uncomplicated colitis were all more likely than healthy controls
to have been exposed to a family member with diarrhea in the
seven days before the onset of symptoms. This suggested a
person-to-person transmission of VTEC [15—17], also a plau-
sible explanation for most cases of sporadic HUS [6]. Another
case-control study by Keen et a! [18] found that an outbreak of
21 cases of hemorrhagic colitis (3 with HUS) caused by E. co/i
0157:H7 was associated with swallowing fecally-contaminated
lake water.
Overall, it can be estimated that in North America and Western
Europe about 90% of children with HUS have some evidence of
VTEC infection, with the serotype 0157:H7 in 70% of cases
[13,19—21] (Fig. 1). In turn, the risk of developing HUS in the face
of E. co/i 0157:H7 infection ranges from 9% to 30%. 0157:H7
serotype was not common in Argentinian cases of verotoxin-
induced diarrhea, but without hemorrhagic colitis, complicated or
not by HUS [22]. This suggests that VTEC of serotypes other than
0157:H7 is mostly associated with nonbloody diarrhea. Overall,
bloody diarrhea and elevated polymorphonuclear leukocyte count
on hospital admission are markers of more severe disease and
poor outcome [23, 24].
The relationship between VTEC and atypical HUS is less
clearly established. 06:H12 strain was isolated from the stools of
a patient with post-partum HUS not preceded by diarrhea [25],
and 0111 serotype was found in a young woman on oral contra-
ceptives [26].
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Table 1. A proposal for a new classification of thrombotic
microangiopathies
Total VTEC 0157:H7
Fig. 1. Cases of childhood hemolytic uremic syndrome (HUS) in North
America and Western Europe in which Escherichia coli infection has been
systematically looked for. Cases associated with verotoxin-producing Esch-
erichia coli (VTEC) and 0157:H7 serotype infection are shown. Data are
from Caprioli et al [19], Lior et a! [13], Ludvig et a! [20], and van de Car
et al [21].
Pathophysiology of verotoxin-associated HUS: Overview of
experimental studies
Two distinct verotoxins, verotoxin-l and -2, also known as
Shiga-like toxins because of their close homology with the toxin
produced by Shigelia dysenteriae type 1 [27], cause the human
disease. These are closely related exotoxins encoded in the DNA
of bacteriophages and incorporated into the genome of a re-
stricted number of E. coli O:H serotypes. Strains associated with
HUS can produce verotoxin-1 alone or verotoxin-2, or both.
Verotoxin is formed by a biologically active subunit A, and a
number of B subunits [28] by which the toxin binds to specific
glycolipid receptors. These have a common terminal disaccharide,
Gal a 1—4 Gal, and include two distinct receptor types: galabiosyl
ceramide (Gal a 1—4 Gal-ceramide), and globotriosyl ceramide
(Gal a 1—4 Gal 131—4 Glc-ceramide-Gb3) [29—31]. Gb3 receptors
are expressed in human renal cortex and medulla, and in renal
tubular epithelial cells [32]. Verotoxin apparently specifically
binds to human renal Gb3 receptors [33]. Besides Gb3 and
galabiosyl ceramide receptors, verotoxin—through its B subunit—
also binds to a pentosyl ceramide molecule (P1 antigen) on
erythrocytes which may reduce competition for the binding to
Gb3 on renal glomerular or arteriolar endothelium [34].
In rabbits verotoxin-i induced a reproducible illness with
neurological and enteric features, and endothelial swelling and
luminal occlusion of small arteries and arterioles [351• How-
Verotoxin receptor Tissue lesions
Brain +1- ++
Cerebellum + + + +
Spinal cord + + + +
Colon ++ ++
Kidney —
Heart —
Liver —
Spleen +1—
Lung + +
ever, rabbits challenged with verotoxin-1 purified from E. co/i
378 (70%) 0157:H7 did not develop renal dysfunction. Microvascular
lesions in these animals were confined to the central nervous
system, colon and lung, with no signs of kidney, liver and heart
involvement [36].
These findings stimulated subsequent studies to see whether the
distribution of verotoxin receptors explained the different organ
localization of the lesions. It was found that in the rabbit the
galabiosyl ceramide receptor and Gb3 were expressed in the
central nervous system and in the gastrointestinal tract and lung
respectively, but kidney, liver and heart did not have verotoxin
receptors. These findings have been taken to suggest that the
distribution of verotoxin receptors governs the localization of
microvascular lesions [36] (Table 2).
In 1955 Neter used the term enteropathogenic E. co/i [37] to
refer to O:H serotypes associated with outbreaks of infant diar-
rhea in the 1940s and 1950s in Europe and North America. The
virulence of enteropathogenic E. co/i depends on their adhesion
to the intestinal mucosa. These coli bacteria, by adhering to the
apical enterocyte membrane, promote local destruction of brush
border microvilli, that is, "attaching and effacing" (AE) lesions.
Human duodenal biopsies have shown that enteropathogenic E.
co/i elongate and disrupt brush border microvilli and, by distorting
the enterocyte apical membrane, produce the characteristic "cup-
like pedestal structures" [38].
A plasmid-encoded bundle-forming pilus (BFP) has been re-
cently described that mediates adhesion of E. coli to cultured
mammalian cell lines. Whether BFP is the adhesin involved in
initial cell attachment remains to be confirmed [38, 39]. By
fluorescence actin staining Jerse et al [40] identified a chromo-
somal gene designated eae (forE. coil attaching and effacing) that
encodes a 94 kDa outer membrane protein and is required for AE
lesion formation.
Upon binding to specific receptors [41], E. co/i and Shigel/a
dysenteriae localize on the colonic mucosa, invade epithelial cells,
multiply and cause cell death. This normally gives diarrhea, but
only strains that produce Shiga-like toxins damage the vasculature
of the mucosa, causing hemorrhagic colitis [421.
Fontaine, Arondel and Sansonetti [43j created a tox-isogenic
strain of S. dysenteriae 1 by modification of the wild-type strain.
The Shiga toxin gene was inactivated by insertion of foreign
genetic information into the gene for the A-subunit of the Shiga
toxin. The newly created isogenic strain was therefore identical to
the wild-type parent, but produced only defective A-subunit
protein. Monkeys were then challenged orally with the wild-type
- Associated with
Verotoxin
Pregnancy
Systemic disease and malignant hypertension
Cancer and chemiotherapy
Transplantation and cyclosporine
Human immunodeficiency virus infection
- Idiopathic
- Familial
Table 2. The distribution of verotoxin receptors determine tissue injury
localization in rabbits given verotoxin-1
544600
450
a)
a)
300
150
From Zoja C. et a! [36].
478 (88%)
0.
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or tox-isogenic strain of S. dysenteriae. Their response was similar
in that both strains caused gastrointestinal distress, but only the
wild-type caused gastrointestinal vascular damage.
In humans, enteropathogenic strains of E. coli and Shigella
dysenteriae cause hemorrhagic colitis by a direct effect on the
colonic mucosal vasculature. Microvascular damage develops at
target organs when the toxin gains access to the systemic circula-
tion. Whether translocation of the toxin from the bowel to the
circulation requires a specific interaction between bacteria and
the epithelial cell or whether free toxin crosses the mucosal
barrier is not known. Binding studies established that the toxin
binds stably (kD 0.1 nM) to approximately 106 receptors available
on each endothelial cell and becomes internalized within two
hours [44]; protein synthesis is then inhibited within 30 minutes.
That these events are indeed caused by Shiga-like toxin is
suggested by data regarding binding inhibition and neutralization
of cytotoxicity by monoclonal antibodies that recognize the beta-
subunits of the toxin. It is clear that a key determinant of
susceptibility of cells to Shiga-like toxin is the number of high-
affinity receptors [45].
Thus cell viability and protein synthesis of endothelial cells
of the kidney were reduced by 50% upon exposure to 1 M
Shiga-like toxin, whereas endothelial cells of umbilical vein
were viable up to >1 nM exposure to the toxin. Basal levels of
Gb3 were approximately 50 times higher in renal endothelial
cells than in the umbilical endothelial cells [46]. After binding,
the toxin penetrates the cytosol by endocytosis.
In contrast to other glycolipid-binding toxins, such as tetanus
and cholera, that are endocytosed from uncoated areas of the cell
membrane, Shiga-like toxin is endocytosed from coated pits [47].
Ultrastructural studies and experiments based on toxicity tests
have all consistently found that Shiga-like toxin rapidly enters the
endocytic compartment with a kinetics of endocytosis similar to
that of other ligands, such as transferrin and epidermal growth
factor, that are rapidly removed from the cell surface by the
coated pit/coated vesicle pathway. Shiga-like toxin is then trans-
ported to the Golgi region. This transport is inhibited at 18°C, a
temperature that reduces the cell's sensitivity to the toxin by more
than 100-fold [471. Binding studies with a Shiga-like toxin-horse-
radish peroxidase conjugate showed that after endocytosis, Shiga-
like toxin is transferred retrogradely from Golgi complexes to the
endoplasmic reticulum cisterns and even to nuclear envelopes
[48]. During internalization, the A subunit of the toxin dissociates
from the B subunits. Approximately 10% of the A subunit protein
is removed in a trypsin-like process, resulting in a maximally active
27 kD subunit enzyme. This fragment is a direct inhibitor of
protein synthesis and is responsible for the cytotoxic action of the
toxin. Shiga-like toxin selectively inactivates 60S ribosomal sub-
units by removing one nucleotide in the 28S ribosomal RNA in a
nucleotide-specific manner [49]. The corresponding functional
lesion caused by Shiga-like toxin inactivation of ribosomes is at
the level of peptide elongation.
Eukaryotic elongation factor-i (eEF-1)-dependent binding of
aminoacyl-tRNA to ribosomes is the primary step that is inhib-
ited. However, the toxin-modified site on 60S ribosomes appears
to involve the binding sites for both eEF-1 and eEF-2, so
Shiga-like toxin secondarily inhibits eEF-2 dependent transloca-
tion of aa-tRNA from the ribosomal A to the P site [50].
Role of inflammatory mediators in the pathogenesis of
verotoxin-induced endothelial cell damage
Lipopolysaccharide (LPS, endotoxin) can combine with Shiga-
like toxin to amplify its cytotoxic potential. Louise and Obrig [51]
found this synergism was dose-dependent on umbilical vein and
renal endothelial cells in culture, and was maximal after preincu-
bating the cells with endotoxin. Endotoxin alone transiently
inhibited protein synthesis by umbilical vein endothelial cells and
enhanced the protein synthesis-inhibiting activity of Shiga-like
toxin. A similar synergism has been demonstrated between Shiga-
like toxin and TNF-a [52]. Preincubation of umbilical vein
endothelial cells with TNF-a increased specific binding sites for
1251-VT-1 10- to 100-fold, and up-regulated cell-surface-associ-
ated verotoxin receptors. This increase mainly occurs through the
TNF receptor 55 upon protein kinase C activation [53]. Given the
frequent finding of endotoxemia in HUS [54], conceivably endo-
thelial cell damage results from the toxic effect of Shiga-like toxin,
added to the effects of endotoxin and endotoxin-elicited IL-1!3
and TNF-a [52]. Siegler et al [55] did in fact find elevated levels
of TNF-a in the urine of children with HUS, very likely reflecting
activation of glomerular macrophage [56] and mesangial cell [57,
58].
Additionally, mice defective in macrophage response to endo-
toxin, which do not produce TNF, are less sensitive to the lethal
effects of verotoxin [591. Low concentrations of endotoxin and
TNF-a, if given in combination, enhanced endothelial-verotoxin
binding and toxicity, and this may have implications for the
pathophysiology of HUS. Low concentrations of endotoxin (that
migrates from the gut into the circulation) in the prodromal phase
of hemorrhagic colitis may increase the sensitivity to verotoxin. In
vitro data suggest that renal endothelium, pre-exposed to endo-
toxin and endotoxiri-derived TNF-a and IL-lp, is far more
susceptible to verotoxin damage [60], so a high local concentration
of inflammatory cytokines may have a pathogenic role in HUS. It
is also possible that renal endothelial cells have a genetic program
that renders them uniquely responsive to verotoxin. Of interest in
this context are recent findings that verotoxin induces TNF-a
biosynthesis in the kidney, but not in other organs or tissues, and
that such an effect is potentiated by endotoxin [61].
In vitro, verotoxin increases neutrophil adhesion to endothelial
cells, an effect enhanced by pre-exposure to TNF [62]. This
constitutes an additional pathway—very likely mediated by a
direct effect on endothelial and leukocyte adhesive molecules—by
which verotoxin may cause vascular endothelial damage. This is
further suggested by findings that neutrophils from children with
diarrhea-associated HUS had increased adhesion to endothelial
cells and caused endothelial injury [63]. Glomerular capillary
endothelial cells are particularly susceptible to verotoxin-induced
increased adhesiveness for neutrophils and monocytes [64].
Shear stress as a possible cause of abnormal endothelial cell
processing of von Willebrand factor
A number of endothelial cell abnormalities have been reported
in HUS and its related syndrome trombotic thrombocytopenic
purpura (TTP). In both syndromes the vessels form less prosta-
cyclin (PGI2) than normal and serum binding capacity for PGI2 is
reduced [65—69]. The former are indirect measurements but the
reduced urinary excretion of the renal metabolite of PGI2,
6-keto-PGF1 (that returns to normal in remission) [70] provides
A Shear stress-induced von Willebrand factor
fragmentation In normal plasma
0.8 6
01
-2
&0.6
0.5
FZ PI 1t :
0 1500 3000 4500 6000
Shear rate/sec
B von Willebrand factor fragmentation
in HUS and UP
82.5±7.790 81.8±4.0 *
T 19.6±3.6
80 68.0±6 10.1±5.2 20
1912 J H:
Coisols Acute Husdrrp Remsion
Remuzzi and Ruggenenti: HUS 5
strong evidence that children with acute HUS form less PGI2 than
normal.
Additional evidence of vascular endothelial cell dysfunction is
that plasma from patients with HUS or TTP often contains
unusually large von Willebrand factor (vWF) multimers. These do
not normally circulate but are stored in the endothelial cell
Weibel Palade bodies, and their presence in the peripheral blood
can only reflect endothelial cell damage. Moake et al [71] initially
found unusually large vWF multimers in the plasma of four
patients with relapsing TTP during clinical remission but not
during relapses. This absence of high molecular weight multimers
during the acute phase [71—741 has been interpreted as resulting
from their enhanced capacity to bind activated platelets. In HUS,
however, the largest multimers were reduced in the acute phase in
some studies and returned to normal after the platelet count
normalized.
In another study children with acute HUS had elevated levels of
the high molecular weight multimers [74] which returned to
normal when patients improved, but remained abnormal in
relapsing cases. Plasma samples collected within the framework of
an international registry from 22 patients with acute TTP and
HUS showed a loss of larger multimers in 15 cases, normal
multimers in six and unusually large multimers only in one [75].
Why is there such a varied pattern of abnormalities in vWF
multimeric structure? A technical answer is that, unless blood is
collected with protease inhibitors, the loss of large vWF multimers
may simply be an in vitro artifact resulting from the factor's
extreme susceptibility to proteolytic cleavage [76—791. vWF frag-
mentation in vivo has been documented by collecting plasma into
an anticoagulant with a cocktail of protease inhibitors added.
Plasma from patients with acute HUS/TIP had a relative decrease
in the intact 225 kD subunit with an increase in the 176 kD
fragment. Almost all these patients had larger than normal
multimers in the circulation. In patients who survived the acute
phase of the disease, abnormal fragmentation could no longer be
found nor were there any large multimers [801.
A major factor to explain the persistence of endothelial cell
dysfunction in HUS is fluid shear stress. Shear stress changes—the
tractive force produced by blood flowing over the endothelial cell
surface—have a profound influence on the pathophysiology of the
vascular endothelium and act as a factor in vWF handling by
enhancing its susceptibility to proteolytic cleavage [81]. A recent
study [81] found a shear rate-dependent loss of the largest
multimers when normal plasma was perfused through long capil-
lary tubes at shear rates normally encountered in the circulation.
As the large multimers decreased, the smaller multimers, includ-
ing the 200 and 350 kD bands, increased. These bands are the
dimers of the 140 kD and 176 kD fragments [81]. Increased shear
forces in damaged microvessels may therefore account for the
abnormal vWF fragmentation observed during the acute phases of
HUS and TTP (Fig. 2), and serve to amplify and propagate
microvascular lesions.
Whether inhibitors of fibrinolysis or enhanced thromboxane
biosynthesis are also of pathogenic importance in HUS remains to
be established.
Nitric oxide-mediated oxidant injury
Beside its effect on vWF, shear stress also influences endothelial
nitric oxide (NO) synthesis and release. NO is a multifunctional
derivative of L-arginine with vasodilatory and cytotoxic properties
Fig. 2. The pattern of von Willebrand factor (vWF) fragmentation induced
by shear stress in normal plasma A, modified from Tsai et al [81]) mimic/cs
the one observed duthig the acute phase of Hemolytic Uremic Syndrome
(HUS) and thrombotic thrombocytopenic Purpura (TTP) B, modified from
Mannucci et al [80]). Symbols in A are: () large multimer fraction; ()
176 kD fragment dimer. Symbols in B are: () 225 kD subunit; () 176
kD fragment dimer. *P < 0.05.
[821. An increased flow rate in vitro consistently released NO from
vascular endothelial cells [83], and exposure of endothelial cells to
laminar shear stress in a cone-and-plate apparatus dose-depen-
dently increased NO synthesis [84]. Laminar shear stress also
up-regulated NO synthase mRNA [84] which can be taken as
evidence that shear forces influence the NO synthase gene.
NO is also a potent mediator of vascular damage and evidence
is available that the arginine analogue N-monomethyl-L-arginine,
which blocks NO formation, protects experimental animals from
immune-mediated vascular injury [85]. Thus, shear stress-medi-
ated overproduction of NO could operate as a major toxic factor
for the very cells that produce it, as well as for neighboring cells.
Damage to cultured endothelial cells upon exposure to endotoxin
or TNF-a is an example of NO autotoxicity [86]. Since NO in turn
causes TNF-a and IL-i release by inflammatory cells [87] and
promotes leukocyte activation, this may further amplify the in-
flammatory damage.
We previously discussed the potential role of neutrophil acti-
vation in the pathophysiology of HUS. However, no data are
available on the biochemical mechanism(s) responsible for endo-
thelial dysfunction upon neutrophil activation. Evidence has
emerged in recent years that most of the toxic effects of neutro-
phil-derived oxygen radicals are actually mediated by NO that
interacts with O2 to form peroxynitrite, further transformed into
H0, the most potent and toxic oxygen-derived radical product
known to date [88]. Findings that malonyldialdehyde levels are
significantly elevated in plasma from patients with HUSITFP
corroborate the evidence of leukocyte activation in this disease
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and suggest reactive oxygen radical formation and lipid peroxida-
tion [89]. Possibly in HUS NO, released by endothelial cells in
response to the initial insult, serves to amplify endothelial damage
through its direct cytotoxic potential as well as by interacting with
leukocyte-derived oxygen radicals.
Current understanding of the clinical syndrome and of the
nature of renal vascular damage
Diagnosis of HUS is based on microangiopathic hemolytic
anemia, thrombocytopenia, and renal failure [75]. Weakness,
pallor and purpura reflect severe anemia and thrombocytopenia.
Hemoglobin may fall below 5 g/dl, but most often is in the range
of 8 to 10 g/dI. Hemolysis probably results from mechanical
fragmentation of red cells traversing the microvasculature par-
tially occluded by platelets and fibrin. Increased lipid peroxidation
and reduced antioxidant activity additionally suggest enhanced
erythrocyte susceptibility to oxidative hemolysis [90, 91]. Young
erythrocytes have GPIb-like and GPIIb-IIla-like receptors that
bind ultra large (UL) vWF multimers. Thus, in HUS erythrocytes
adhering to the endothelium by ULvWF molecular bridges may
be disrupted by the increased shear stress in the microcirculation
[92, 931 Whatever the mechanism of fragmentation, red blood
cells acquire aspects of burrs, helmet cells, or schistocytes that
have diagnostic value if found in the peripheral smear. Reticulo-
cyte count is almost invariably high. Markers of hemolysis include
high lactate dehydrogenase (LDH) and plasma hemoglobin, and
low or undetectable haptoglobin [94]. Hyperbilirubinemia (un-
conjugated fraction) is common.
Thrombocytopenia reflects intravascular platelet clumping (a
likely consequence of endothelial injury). Platelet count usually
ranges from 30 x 10°/liter to 100 x 10°/liter at presentation,
though lower or near-normal counts are found infrequently.
Neither platelet count nor duration of thrombocytopenia (from a
few days to two or three weeks in the average patient) predicts the
outcome of the disease [95]. In HUS the thrombocytopenia is
rarely so severe as to cause purpura or bleeding. Clotting tests are
usually in normal ranges, and the fibrinogen turnover is only
slightly increased and only at the onset of the disease.
Epidemic HUS
Typical (epidemic) HUS is associated with prodromal diarrhea
and is also referred to as D+HUS. Leukocyte count more than
20,000, high hemoglobin levels (about 10 g/dI) and male sex are
predictors of poor outcome [96]. In a series of 282 children with
D+HUS who entered the U.K. collaborative study from April
1985 to 31 March, 1988 [97] the yearly incidence of the disease
was about 1/100,000, with a peak in children aged one to two years
(3.3/100,000/year) and between April and October. The male:
female ratio was 1:1.1 in children less than 10 years old and 1:2.4
in children aged 10 or more. Diarrhea ensued abruptly and was
bloody in 71.6% of cases. Verotoxin or VTEC in stools was found
in 62% of cases; 62% of children needed dialysis and 5% died
during the acute phase. The initial neutrophil count was signifi-
cantly higher in patients who developed oligoanuria. Hyponatre-
mia was associated with an increased risk of seizures (84% of
cases with hyponatremia had seizures as compared with 50% of
cases without low sodium). At one year no patient was on chronic
dialysis (Table 3).
Table 3. Clinical and laboratory features of childhood D + and D —
HUS and adult HUS
Adult
D+ HuS' D- HUSH HUS'
Short term outcome
- Cases reported 282 16 50
- Seasonal onset Spring/summer any any
-Male/female 1:1.2 2.2:1 1:1
- Secondary forms 0 0 23
- Acute dialysis 175 (62%) 9 (56%) 30 (60%)
- Died 15 (5.2%) 3 (19%) 7 (14%)
One year outcome
- Cases reported 182 11 43
- Hypertension/renal 19 (10%) 2 (20%) 14 (32%)
failure
- Chronic dialysis 0 5 (45%) 11(26%)
From a Milford [95] and Schieppati et al [1141
These data confirm previous evidence that the majority of
patients with classical D + HUS usually recover within two or three
weeks without sequelae and that the acute mortality rate has
decreased from the 40% of the earlier series [98] to about 6%
[99]. However, studies on renal function ten years after HUS
indicate that only 60% recover completely [100] and half of the
patients may have a GFR below 80 ml/min/1.73 m2 [101]. Extent
of histologic damage is the best predictor of long-term prognosis,
rather than the initial clinical severity of the disease.
In a French series, 15 to 25 years after an episode of classical
childhood HUS, only ten of 25 patients had no renal abnormali-
ties. Of the remaining 15 patients, four had reached end-stage
renal failure, three had chronic renal failure and eight had
residual proteinuria or hypertension. All these patients with
residual renal disease had either patched cortical necrosis or
TMA involving at least 50% of the glomeruli at the time of disease
presentation [102].
D+HUS is mainly a disease of childhood, though no age group
is exempt, with a slight prevalence of females among older
children. Caucasians are more commonly affected, with peak
incidence in Britain, South America and India. There is a
well-defined seasonal incidence with most cases in the warmer
months, typically with epidemic outbreaks [103]. Gastrointestinal
symptoms usually precede full manifestation of the disease and
may be followed by a symptom-free period. Hemorrhagic colitis
presents with abdominal cramps and watery diarrhea followed by
a discharge resembling lower gastrointestinal bleeding. Barium
enema indicates filling defects (pseudotumors) that are also
features of HUS with bloody diarrhea. In some instances vero-
toxin-associated colitis may mimic surgical emergencies including
appendicitis [1041, acute ulcerative colitis with megacolon [105],
or intestinal intussusception [98], occasionally involving unneces-
sary laparotomy that increases mortality. However, some individ-
uals may really need a hemicolectomy for bowel infarction or
perforation [106]. These cases carry the worst prognosis. Shigel-
losis-associated HUS also has a high mortality rate (about 30%)
and may he associated with systemic intravascular coagulation,
acute cortical necrosis and renal death [107, 108].
Gastrointestinal losses may cause hypovolemia and, in combi-
nation with hemoglobinemia, hyperbilirubinemia and hyperurice-
mia may favor acute renal failure. Renal symptoms include
macro- or microhematuria, proteinuria (occasionally nephrotic)
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oligoanuria or polyuria. Oligoanuria may lead to fluid retention
and hypertension that in concomitance with uremia and anemia,
and occasionally myocarditis [1091 or pericarditis [110], may
precipitate congestive heart failure. Prolonged oligoanuria or
persistent hypertension are markers of more severe disease often
leaving residual renal impairment. Uremia and hyponatremia may
concur with neurological dysfunction which often manifests with
somnolence, confusion, seizures and coma. Most cases have signs
of TMA of the brain, occasionally with infarctions or hemor-
rhages, but there are reports of abnormal brain pathology but no
evidence of vascular lesions [111]. The neurological symptoms
usually subside with the remission of the disease, but sequelae
including developmental retardation, learning and behavioral
problems, focal motor deficits and convulsions may persist for
years [112].
Sporadic HUS
Atypical (sporadic or D-HUS) manifests without prodromal
diarrhea in children of all ages and in adults, and accounts for
about 5 to 10% of all cases [97]. It may be familial and frequently
follows a relapsing and progressive course. In a series of 16
children, 13 had respiratoly symptoms or vomiting at presenta-
tion. One had autosomal dominant HUS. In contrast to D+ cases,
these patients had no evidence of VTEC infection, none of the
family contacts had concurrent illnesses and no seasonal distribu-
tion was observed; 56% of patients needed dialysis and 27% died.
At one year, five patients were on chronic dialysis. Overall
one-year mortality/morbility was 91% in children with D-HUS,
compared to 18% in children with D+HUS [95].
In a further series of 21 children with atypical HUS—ten with
a relapsing form—five died (3 of septicemia and 2 after intracra-
nial hemorrhage and intracranial infarction, respectively), four
progressed to end-stage renal failure, 11 had residual hyperten-
sion and/or proteinuria, and only one completely recovered [113].
The Italian Group of The International Registry of Haemolytic
Uraemic Syndrome [114] has recently reviewed the clinical course
of 50 adults with sporadic HUS. Mean age at onset was 34.3
18,3 years. Males and females were equally affected. No seasonal
trend in presentation was observed. In 23 patients HUS was
associated with cancer, pre-eclampsia, malignant hypertension, or
vasculitis. Thirty patients (60%) required dialysis during the acute
phase. Six died during the acute phase because of neurological
complications and one died later after discharge (overall mortality
16%). After one year of follow-up of 43 survivor patients, 11
(26%) had recovered normal renal function, 14 (33%) had
hypertension and/or renal insufficiency and 11 (26%) were on
regular dialysis. Prognostic factors of survival and recovery of
renal function were older age, which was associated with higher
mortality in the acute phase, and severe renal involvement at
onset (as expressed by elevated serum creatinine) which had a
worse long-term prognosis [114].
Pregnancy-associated HUS
Pregnancy-associated HUS may occasionally develop as a com-
plication of pre-eclampsia [115, 116]. Some patients progress to a
life-threatening variant of pre-eclampsia with severe thrombocy-
topenia, microangiopathic hemolytic anemia, renal failure and
liver involvement [117, 118]. This syndrome is often associated
with coagulation abnormalities, with disseminated intravascular
coagulation in 30% of cases [116, 119]. The microangiopathic
process almost invariably involves the placenta and produces fetal
distress. Swelling of the glomerular tufts due to an increase in the
cytoplasm of the endothelial cells and thickening of the basement
membrane (known as capillary endotheliosis) with sub- or inter-
endothelial fibrinoid deposition have been reported [116]. HUS or
its complications in pregnancy are always an indication to prompt
delivery that is usually followed by complete remission.
Post-partum HUS
Post-partum HUS is another complication of pregnancy that
manifests within three months of delivery in most cases. VTEC
infection is one of the possible triggers [120]. Renal function
deteriorates suddenly and severely [121]. Blood pressure may be
normal at the onset, but hypertension almost invariably compli-
cates the course of the disease. Additional features include fever
and neurological involvement, and in such cases the disease
resembles TIP. The mortality rate is high ranging from 50 to 60%
[122, 123], while residual renal dysfunction and hypertension are
the rule in surviving patients, despite occasional reports of
complete recovery of renal function [122, 124, 125]. HUS associ-
ated with the birth control pill is not a distinct entity since no
causal relationship has ever been clearly established.
Cancer- and mitomycin-associated HUS
Cancer- and mitomycin-associated HUS complicates almost
6% of cases of metastatic carcinoma [126]. Gastric cancer alone
accounts for about half such cases. These patients have an
extremely poor prognosis and most of them die within weeks. A
form of TMA resembling HUS has also been described in
cancer patients given the anticancer drug mitomycin. Chemo-
therapeutic combinations containing platinum or bleomycin
may also trigger HUS. The risk of developing HUS after
mitomycin-C therapy is 2% to 10% [127]. Manifestations are
dose related, so that cumulative doses higher than 60 mg are
almost invariably associated with the disease. Interestingly,
mitomycin added to cultured human umbilical cord vein endo-
thelial cells inhibits prostacyclin production and cell prolifera-
tion [128]. The case fatality rate of mitomycin HUS is 60% to
70%, and the median time to death is about four weeks. Deaths
occurring within the first few months are usually related to
complications of the syndrome, including renal failure and
pulmonary edema, or sepsis. Patients surviving the acute phase,
may have remission of the microangiopathic process but re-
main on chronic dialysis.
CsA -associated HUS
Cyclosporine A (CsA)-associated HUS was reported by
Powles et al [1291 in a patient treated with CsA to prevent
graft-versus-host disease after allogenic bone marrow trans-
plantation. Since then HUS has been reported in many patients
after bone marrow [129, 130], liver, heart, and kidney trans-
plant [131] who were receiving chronic CsA. The prognosis is
poor in such cases although anecdotal reports indicate that
plasma manipulations may improve the outcome [131, 132].
Cases of CsA associated arteriolopathy resembling HUS have
been reported in kidney graft recipients [130, 133], but it is still
not clear whether these are cases of HUS or of acute vascular
rejection. Recurrent HUS in patients who had received a renal
transplant for terminal renal failure and a previous history of
HUS is another debated issue {134—136J. Hebert, Sibley and
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Fig. 3. Electron micrograph of a glomerular capillaty in hemolytic uremic syndrome. The endothelium is detached from the glomerular basement
membrane, the subendothelial space is widened and occupied by electron-lucent fluffy material. Foot processes are extensively fused (magnification X
7000).
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Table 4. Specific treatments for HUS
Plasma manipulation
- Infusiona
- Exchangea
Antithrombotic agents
- Heparin
Antiplatelet agents
- Acetylsalicilic acid
- Dipyridamole
- Prostacyclin
Other treatments
- y globulins
- Vitamin E
30-40 ml/kg on day 1, then 10-20 mI/kg/day
1—2 plasma vol/day
10,000—20,000 U/day
325—1500 mg/day
400—600 mg/day
4—20 ng/kg/day
400 mg/kg/day
1.000 mg/m2/day
- Probably effective to ameliorate renal and neurological sequelae
- Use suggested in atypical and adult HUS and in all the forms with
neurological involvement
- As effective as infusion, no risk of fluid overload
- Some benefit hypothesized in post-partum HUS; uneffective in
childhood HUS
- Increased risk of bleeding
- Unproven effectiveness in HUS
- Unproven effectiveness in HUS
- Benefit reported in occasional cases, may cause hypothension and
worse diarrhea
- May improve neurological signs. Unproven long term benefit in
HUS; may cause anaphylaxis and severe infection
- May improve renal outcome in childhood HUS; to be tested in
controlled studies
a In cases resistent to whole plasma, the infusion or exchange of plasma cryosupernatant may be effective [181]
Mauer [1361 found an high frequency of recurrent HUS in
children who received living-related donor transplants. Pirson
et al [137], however, were unable to confirm this. Among 12
children and four adults who had a renal transplant after HUS,
only one adult had acute, transient hemolysis on day 10 after
surgery. Gagnadoux, Broyer and Habib [138] found no recur-
rence of HUS in 25 children receiving three living-donor and 28
cadaver kidney grafts. According to these authors, although
recurrent HUS is exceptional, graft loss due to chronic vascular
rejection was somewhat more frequent among patients who
had a transplant after HUS than those transplanted after a
non-HUS type of disease.
HI V-associated HUS
Human immunodeficiency virus infection-associated HUS was
first reported in 1984 in a homosexual man [139]. Since then,
TMA diagnosed as either HUS or TFP is part of the complica-
tions of AIDS and accounts for up to 30% of hospitalized cases of
HUSITFP at least in some institutions [140]. VTEC infection
[1411 and cocaine abuse [142] are possible triggers. The clinical
course is poor and depends heavily on the severity of the
underlying disease.
Age and HUS
Renal lesions of HUS are quite different in infants and small
children, older children, and adults. In children under the age of
two the disease mainly affect glomeruli with thickening of the
capillary wall and endothelial cell swelling with reduction of the
glomerular capillaries that may be occluded by thrombi. Endothe-
hum is detached from the glomerular basement membrane
(GBM) by electron lucent, finely granular material bounded by a
thin layer of newly formed GBM (Fig. 3) that accounts for the
double contour appearance of the glomerular capillary wall [143].
Arteriolar damage is rare [144]. In biopsies taken several months
after the initial insult most glomeruli appear normal and in most
cases renal function recovers completely [144].
In older children and adults glomerular changes are more
severe and heterogeneous [123, 125, 145] and the classical lesion
of TMA is less frequent. Glomeruli show ischemic changes with
retraction of the tuft and thickening and wrinkling of the capillary
wall [145] (Fig. 4). Occasional glomeruli have necrotic areas
and/or segmental extracapillaty proliferation. Renal biopsies
taken in the earlier phases of the disease show changes reminis-
cent of those of younger children [125, 146—149].
The question of mesangiotysis in HUS (Fig. 5) is controversial:
it seems to be a rather non-specific lesion that is also found in
malignant hypertension [150], radiation nephritis [151], glomeru-
lonephritis [152, 153] and diabetic glomerulosclerosis [154]. Tu-
bular and interstitial changes generally are patchy and depend on
the distribution, severity and chronicity of glomerular and vascu-
lar lesions. Renal arterioles and arteries are commonly involved
[123, 125, 148] with severe narrowing of the lumina due to
subendothelial expansion (Fig. 6). The affected arteries are mostly
interlobular and show intimal swelling and proliferation (a con-
sequence of accumulation of red blood cells and fibrin that
infiltrate the artery wall), with thrombosis and necrosis of the wall
(Fig. 7). Myointimal cells can be elongated and arranged in
whorled concentric patterns giving an onion-like configuration.
Occasionally aneurysmal dilation of arterioles forms glomeruloid
structures that have been attributed to endothelial cell prolifera-
tion [155].
Impact of new knowledge on treatment
Typical HUS in children, including verotoxin-associated forms
Correction of fluid and electrolyte abnormalities by dialysis has
probably had a major role in the overall spectacular improvement
of short-term survival in HUS. Antibiotics do not alter the course
of enterohemorrhagic E. coli infection. There are data that
exposure of E. coli 0157:H7 to sulfamethoxazole or trimethropim
in vitro increases toxin production, while ciprofloxacin may reduce
it [156]. Cases of Shigella dysenteriae-associated HUS have to be
given ampicillin or trimethropim-sulfamethoxazole in resistant
cases [157]. In occasional cases, enterohemorrhagic colitis
progresses to severe ischemic bowel disease and perforation, that
may require colectomy. Specific therapies including corticoste-
roids, heparin, streptokinase, antiplatelet agents and prostacyclin,
were found of no benefit in cases of childhood typical HUS
a' — — . '
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Fig. 4. Glomerulus from a patient with hemolytic uremic syndrome. Severe ischemic changes have occurred, characterized by retraction of the glomerular
tuft and marked thickening and wrinkling of the capillary wall (silver stain; magnification X 400).
reported from 1964 to 1980 (Table 4) [158, 159]. Proesmans and
Eeckels, in their meta-analysis of cases published up to 1974,
showed that survival was significantly better in heparin-treated
HUS than in cases who did not receive anticoagulants [1601. The
difference was even more striking when only severe cases were
considered. In subsequent years several retrospective studies,
mainly uncontrolled with small number of patients, were incon-
clusive [161, 162]. To now, only three prospective studies are
available. In the study by Vitacco, Sanchez-Avalos and Gianan-
tonio [163] heparin was used in 10 of 30 severe cases of childhood
HUS and appeared to worsen the outcome of the disease. In a
randomized study, Loirat et al [164] detected no differences in
duration of hemolysis, thrombocytopenia and oliguria or in renal
pathology and long-term renal function in 15 children with HUS
given heparin and urokinase as compared to 18 controls who only
had symptomatic treatment. However, in four patients antithrom-
botic therapy was associated with severe hemorrhages and discon-
tinued. Similarly, Van Damme-Lombaerts [165] found no differ-
ences in duration of disease, outcome and renal pathology in 58
children with HUS randomly given heparin plus dipyridamole or
supportive therapy alone.
Streptokinase and urokinase have definitely been associated
with more hemorrhages and should not longer be used. Infusion
of vitamin E (es-tocopherol, that prevents lipid peroxidation) gave
encouraging results in uncontrolled studies. In 16 children with
HUS, 14 of whom were oliguric and 11 required dialysis, oral
vitamin E at the dose of 1 gIm2 per day for at least a week was
associated with a good clinical course [166]. All patients survived,
with normal renal function in all but one three months later.
These results are better than those of a comparable group of
children given heparin, streptokinase, or antiplatelet agents and
would appear to support the use of vitamin E in children with
HUS, but larger controlled studies are needed to establish this
more formally. A double-blind controlled study by Sheth, Gill and
Leichte [167] found that intravenous infusion of y-globulins had
no long-term benefits in 20 children with HUS. Thus, the risks of
intravenous y-globulins, that include anaphylaxis [1681 and bac-
terial or fungal (Candida albicans) infections secondasy to inhibi-
tion of Fc receptor-mediated immune clearance of circulating
microbial pathogens [169J, advice against their use as first choice
therapy for HUS.
From 1980 some patients have been given plasma infusion or
plasma exchange with fresh frozen plasma [170]. Publications on
pediatric cases with classic HUS given plasma manipulation is
sparse. Sheth et al [171] found that the duration of anemia and
thrombocytopenia and incidence of residual renal or neurological
'1
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Fig. 5. Glomerulus from a patient with hemolytic-uremic syndrome revealing marked ischemic changes and mesangiolysis (silver methenamine; magnification
x 450).
abnormalities were comparable in 12 children given fresh frozen
plasma and in 31 historical controls. Ogborn, Crocker and Bar-
nard [172] retrospectively compared the outcome of 18 children
with typical HUS treated with hemodialysis and plasma infusion
and 18 on hemodialysis alone. Severity of the disease, length of
hospital stay, duration of renal dysfunction and disease-related
complications were all comparable. At discharge the prevalence
of hypertension was higher in the plasma group than in the
controls.
Rizzoni et al [173] did a controlled study of plasma infusion in
32 children with severe HUS whose inclusion criteria included
hospital admission within eight days of onset, renal failure severe
enough to require dialysis, and transfusion not in excess of 25
mi/kg. The study group was given 30 mI/kg of plasma at admission
then 10 mi/kg/day until the platelet count exceeded 150,000. The
average number of infusion days was 9.7. The control group had
supportive therapy alone. No significant benefit of plasma in the
acute phase could be demonstrated at 24 months follow-up. Renal
biopsies taken from 11 patients in each group 24 to 49 days after
the onset of the disease showed comparable lesions at light
microscopy. One patient in each group had cortical necrosis, and
none had severe arteriolar changes. Ultrastructural studies of
renal tissue, however, indicated arteriolar damage and thickening
of the lamina rara interna in five of seven control patients, but not
in any of the plasma-treated patients. The French study by Loirat
et al [174] also found comparable blood pressure, serum creati-
nine, and proteinuria at one year follow-up in 39 children treated
with plasma infusion (10 mI/kg/day for 7 days) and 40 controls.
However, renal biopsy studies revealed extensive cortical necrosis
in seven of 27 control patients, but in none of the 27 patients given
plasma.
Thus, plasma infusion appears to improve the renal sequelae in
children with HUS, despite its lack of effects on hard clinical
end-points. However, none of these studies was large enough to
have the power to detect significant differences on major clinical
end-points, including serum creatinine, urinary proteins and
blood pressure. It has been estimated that in order to demonstrate
potential benefit of a given therapy on one or more of these
variables at least 340 patients have to enter a controlled study.
Side effects of plasma treatment in children are not negligible,
beside the risk of infection and fluid overload. The latter can be
avoided by plasma exchange. In two children with HUS, pro-
longed infusion of fresh frozen plasma induced hyperproteinemia,
and increased urinary proteins [175]. In view of the benign course
of typical HUS, the risks and cost of specific treatment outweigh
the potential benefits.
- I S' S T - _____
UI
-'CCL'Td —a..-
12 Remuzzi and Ruggenenti: HUS
Fig. 6. Arteriole from a patient with hemolytic uremic syndrome. The lumen is completely obstructed by thrombotic material. (Masson's trichrome;
magnification X 400).
Recent evidence suggests a potential role for immunization
against Shiga-like toxin in VTEC-associated HUS since pre-
treatment with anti-Shiga-like toxin serum protected piglets
against E. coli 0157:H7-induced brain vascular lesions but not
against diarrhea and colitis (1761. Thus, it is worth investigating
whether commercial immune globulin preparations containing
anticytotoxin neutralizing antibodies are similarly effective in
humans if given early in the course of the disease. Parenteral
immunization with recombinant anti-Shiga-like toxin-i did pro-
tect rabbits against disease induced by the enteropathogenic E.
coil strain RDEC-H19A, suggesting that a parenteral immuniza-
tion strategy might limit verotoxin-related manifestations of
VTEC intestinal infection (1771.
The possibility of trapping and inactivating verotoxin in the
bowel by SYNSORB-PK, a material composed of synthetic oligo-
saccharide verotoxin receptors attached to diatomaceous earth, is
under investigation [1781 and a phase 2 study to assess its efficacy
in preventing HUS in children with bloody diarrhea is planned in
1994 in several Canadian medical centers. However, until new
strategies become available in clinical practice, the general con-
sensus for the moment is that careful supportive management is
still the most appropriate form of treatment.
Atypical forms and adult HUS
Supportive treatment does not generally cure atypical HUS,
adult HUS, chronic-relapsing HUS, familial HUS and all the
forms with central nervous system involvement that usually have a
very poor outcome. Good control of hypertension is mandatory.
Prostacyclin has been used, with positive results in occasional
patients but only after prolonged infusions [1791. However, there
is no clear-cut evidence that these were not cases that recovered
spontaneously after a prolonged course. Infusion is usually started
with 2 to 3 ng/kglmin and progressively increased to 5 to 10
ng/kg/min or until the appearance of tachycardia, hypotension or
abdominal discomfort. One must bear in mind that prostacyclin
infusion may make diarrhea worse in D+HUS [180]. Plasma
infusion or exchange is the treatment of choice in adult or
relapsing forms of HUS and when there are neurological signs
[181, 1821. However, although plasma manipulation induces
prompter hematological remission it is not clear whether plasma
has an effect on renal recovery (Table 4) [1831.
A retrorespective case-control study [1841 on 33 children over
five years of age with low prognostic score found that chronic
renal failure (creatinine clearance <60 ml/min/1.73 m2) and
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Fig. 7. Electron micrograph of an arteriole in hemolytic-uremic syndrome. The vascular lumen is completely occluded. Changes include intimal edema and
myointimal proliferation (magnification >< 1100).
end-stage renal failure were restricted to patients who were not
treated with plasma exchange. However, at the one year follow-
up, renal function was comparable in the two study groups.
Plasma, either infused or exchanged, is contraindicated in
patients with Streptococcus pneumonia-associated HUS, since
adult plasma contains antibodies against the Thomsen-Frieden-
reich antigen, and these may accelerate polyagglutination and
hemolysis. These patients should be treated with antibiotics and
washed red blood cells [185]. Substitution of cryosupernatant
fraction (that is, plasma from which cryoprecipitate containing the
largest plasma vWF multimers has been removed) for whole
plasma during the exchange procedure has been successful in a
small number of patients who either did not respond or did not
respond adequately to repeated plasma exchanges with whole
plasma [181, 1861.
Pregnancy-associated and post-partum HUS
Because of the rarity of this syndrome there are only anecdotal
reports on its therapy [187]. Supportive treatment (that is, dialysis
if necessary and careful fluid management) is the best that can be
done. A 53% survival in heparin treated patients versus 17%
survival in untreated patients was found in a retrospective analysis
of uncontrolled studies in post-partum HUS [1881. However, in
view of the severe hypertension and thrombocytopenia, heparin
and antiplatelet agents enhance the risk of intracranial hemor-
rhage in these patients. There are isolated reports of successful
therapy of postpartum HUS with plasma infusion or exchange but
they are not as convincing as for TIP.
Cancer and mitomycin-associated HUS
Therapy is minimally effective, and includes management of
hypertension and renal failure. Administration of blood products
to correct symptomatic anemia often results in exacerbation of the
syndrome in chemotherapy-associated HUS, with rapid worsening
of hemolysis and renal function, and pulmonary edema [189J.
Treatment modalities that have been studied in other forms of
HUS and TIP, including steroids, azathioprine, cyclophospha-
mide, vincristine and antiplatelet agents, have been attempted
empirically. Since circulating immune complexes may play a role
in this syndrome, plasma exchange may be of value but remission
has seldom been reported. An effective procedure to remove
circulating immune complexes is perfusion of autologous plasma
over filters containing staphylococcal protein A (SPA) covalently
bound to polyacrylamide beads. SPA is a cell wall component of
a pathogenic staphylococcus that non-specifically binds the Fc
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portion of IgG. Korec, Schein and Smith [190] first reported the
complete clearance of circulating immune complexes in eight of
eleven patients treated with this procedure, associated with he-
matological remission in nine cases, stabilization of renal function
in six and long-term remission in seven. A median survival of six
months was reported after the procedure, with a better outcome
in patients with no clinical evidence of residual cancer. Overall the
results with SPA immunoperfusion seem better than with plasma
exchange. Whether this indicates a true superiority of the proce-
dure or simply reflects the selection of less severely affected
patients earlier in the course of the syndrome needs to be
investigated.
Transplant- and cyclosporine-associated HUS
The outcome of post-transplant HUS is poor. Some therapies
effective in other forms of HUS have been tried, but only a
minority of patients recovered renal function while most lost their
graft in a matter of weeks. Early recognition of the syndrome and
discontinuation of CsA has occasionally led to reversal of the
syndrome [131, 191]. FK 506 used in renal transplant patients who
had HUS to replace CsA did not prevent recurrencies [192].
Human immunodeficiency virus infection-associated HUS
Management is the same as recommended for non-AIDS cases.
However, steroids, vincristine and immunoglobulins may increase
the risk of opportunistic infection in already immunosuppressed
patients [169] and should be given with caution. Plasma exchange
or infusions is virtually the only feasible therapy for AIDS-
associated TMA. In one series of seven patients with HIV-
associated TMA the short-term response rate to plasma exchange
(86%) was comparable to the rate (80%) reported in the pooled
literature of non-HIV cases [193]. However, none of these
patients survived more than two years after remission. Sporadic
reports of remission of the syndrome after treatment with the
antiretroviral agent zidovudine [194] and of recurrences after its
withdrawal [195] led people to suggest that zidovudine may have
some use in the management of HIV-related HUS/TFP. How-
ever, cases of HUS/TFP arising during zidovudine therapy make
this very unlikely [1961.
Should we continue to use the name HUS?
Now that we know the cause of 90% of cases of childhood HUS
and of majority of causes of sporadic HUS, we wonder whether
the descriptive name of HUS is still appropriate. Table 1 suggests
a possible alternative definition deriving from the common term
of thrombotic microangiopathy, which, we believe, beautifully
describes the nature of the lesion [197], and classifies the syn-
drome according to what is clear on its causes. We are all deeply
greatful to Gasser et al [198] for inventing the name HUS that
helped identify these patients over the last 40 years and stimulated
so many studies on the pathophysiology of the disease and on its
treatment. However, as we don't use Bright's disease anymore but
rather post-streptococcal, Alport or IgA glomerulonephritis [199],
we suggest that the old name HUS should be abandoned in favor
of a new definition that more precisely reflects the current
knowledge.
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